April 1, 2021
NX Prenatal Announces Initiation of a Clinical Study for the Detection of Placenta Accreta
NX Prenatal Inc. announced today that it is a sponsor and collaborator for an upcoming clinical study whereby its NeXosome® liquid biopsy platform will be key in the detection of biomarkers that can identify pregnant patients with Placenta Accreta Spectrum (PAS). Pregnant moms that have had prior C-sections, or IVF-assisted conception, or prior D&C procedures are known to be in elevated risk categories for PAS, but there is no current blood test that can help identify which of those moms may experience this life-threatening condition.
January 27, 2021
NX Prenatal Expands Leading Patent Position in Exosome-Based Liquid Biopsy Tests in Maternal- Fetal Medicine
NX Prenatal Inc. today announced that it has achieved new patent issuances in both the United States and Europe for its exosome-based liquid biopsy tests for the early identification of pregnant mothers at elevated risk for spontaneous preterm birth. NX Prenatal controls worldwide rights to a portfolio of more than three dozen pending and issued patents that feature the earliest and most comprehensive claims related to the utilization of exosomes for the detection and management of adverse pregnancy outcomes.